2018
DOI: 10.1016/j.jacc.2018.07.092
|View full text |Cite
|
Sign up to set email alerts
|

Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

6
170
0
10

Year Published

2019
2019
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 253 publications
(186 citation statements)
references
References 31 publications
6
170
0
10
Order By: Relevance
“…Our retrospective study was not designed to explore the mechanistic relationship between CTS and CA and did not include a histological analysis of the tenosinovial tissue of patients who underwent CTS surgery. The presence of TTR amyloid in the tenosinovium of patients with CTS has been previously demonstrated (online supplementary Table ), but the co‐existence of CA has been rarely investigated, and when it has, the prevalence was found to be particularly low. In this regard, Sperry et al .…”
Section: Discussionmentioning
confidence: 96%
See 2 more Smart Citations
“…Our retrospective study was not designed to explore the mechanistic relationship between CTS and CA and did not include a histological analysis of the tenosinovial tissue of patients who underwent CTS surgery. The presence of TTR amyloid in the tenosinovium of patients with CTS has been previously demonstrated (online supplementary Table ), but the co‐existence of CA has been rarely investigated, and when it has, the prevalence was found to be particularly low. In this regard, Sperry et al .…”
Section: Discussionmentioning
confidence: 96%
“…The presence of TTR amyloid in the tenosinovium of patients with CTS has been previously demonstrated (online supplementary Table ), but the co‐existence of CA has been rarely investigated, and when it has, the prevalence was found to be particularly low. In this regard, Sperry et al . recently published a prospective study that included 98 patients undergoing CTS surgery and reported a 10% prevalence of TTR amyloid deposits at the time of surgical intervention.…”
Section: Discussionmentioning
confidence: 96%
See 1 more Smart Citation
“…In patients with signs, symptoms, or manifestations suggestive of amyloidosis, diagnostic and genetic testing are of utmost importance. Neurologic and cardiac symptoms can be evaluated with numerous tests and procedures, including tissue biopsy, Congo red staining to confirm the presence of amyloid, and mass spectrometry or immunohistochemistry to confirm the type of amyloid (Figure a,b) (Benson et al, ; Carvalho, Rocha, & Lobato, ; Coelho, Maurer, et al, ; Gilbertson et al, ; Linke, Oos, Wiegel, & Nathrath, ; Sperry et al, ). Genetic testing is required to differentiate wtATTR from hATTR and to allow for the detection of specific TTR gene mutations, which may help predict the clinical course of disease (Coelho, Maurer, et al, ).…”
Section: Discussion/observationmentioning
confidence: 99%
“…Diagnostic workup for polyneuropathy (a) and cardiomyopathy (b) when ATTR amyloidosis is suspected (Carvalho et al, ; Castano et al, ; Coelho et al, ; Conceicao et al, ; Donnelly & Hanna, ; Galat et al, ; Geller, Singh, Alexander, Mirto, & Falk, ; Gertz, , ; Gillmore et al, ; Nativi‐Nicolau & Maurer, ; Ruberg & Berk, ; Sperry et al, ). 99m Tc, technetium‐99m; AL, amyloid light chain; ATTR, amyloid transthyretin; CMR, cardiac magnetic resonance imaging; DPD, 3,3‐diphosphono‐1,2‐propanodicarboxylic acid; ECG, electrocardiogram; echo, echocardiogram; hATTR, hereditary amyloid transthyretin; MRI, magnetic resonance imaging; PYP, pyrophosphate; TTR, transthyretin; wtATTR, wild‐type amyloid transthyretin.…”
Section: Discussion/observationmentioning
confidence: 99%